The molecular structure of the DNA A-tract dodecamer d(CGCAAATTTGCG) complexed with the drug Hoechst 33258 has been determined by X-ray diffraction analysis. The Hoechst molecule binds in the DNA minor groove covering the sequence AATTT of the central A-tract, with the piperazine group close to one of the GC regions. The drug molecule makes two three-centered hydrogen bonds from the nitrogen atoms of the benzimidazole rings to the N3 and 0 2 atoms of the DNA bases. Although a high propeller twist is observed in the A-tract, only one unsymmetrical three-centered hydrogen bond is present in the DNA major groove. The structure is compared with other minor-groove-binding drug complexes and the influence of these drugs on DNA A-tracts is discussed.
Hoechst 33258 [chemical name: 2'-(4-hydroxyphenyl)-

5-(4-methyl-l-piperazinyl)-2,5'-bi-benzimidazole], netropsin
and distamycin are DNA minor-groove-binding drugs with common structural features : (a) they are molecules containing planar segments due to the presence of aromatics groups ; (b) they are non-symmetrical molecules ; (c) they are positively charged and (d) they have an arc-like shape which allows them to follow the minor groove when interacting with the DNA double helix. Furthermore, these molecules have affinity for A+T-rich sequences over G+ C-containing sequences mostly due to steric factors (Burckhardt et al., 1985) . The presence of the N2 amino group in guanine prevents the binding of the drug in the DNA minor groove (Kopka et al., 1985) , although Hoechst 33258 tolerates G-C pairs at the edge of the binding site (Harshman and Dervan, 1985 ; Portugal and Waring, 1988) .
Hoechst 33258 is a synthetic N-methyl piperazine derivative with two benzimidazole groups and one phenyl group (Fig. 1) . It has antihelminthic activity (Lammler et al., 1971) and is commonly used as a fluorescent cytological stain for DNA (Hilwig and Gropp, 1972; Holmquist, 1975) . Hoechst 33258 binds preferentially to A+T-rich regions as determined by fluorescence (Latt and Wohlleb, 1975 ; Holmquist, 1975) , footprinting (Harshman and Dervan, 1985) and '"1-DNA cleavage (Martin and Holmes, 1983; Murray and Martin, 1988) .
There are several X-ray diffraction studies of this drug complexed with two different dodecamers. The complex Hoechst 33258-d(CGCGAATTCGCG) has been reported by The drug has four structural groups: a phenyl ring (Ph), two benzimidazole rings (Bzl and Bz2) and a piperazine ring (Pip). The torsion angles between the four structural groups are indicated with arrows. The N1 and N3 atoms interact with the bases at the floor of the DNA minor groove. Pjura et al. (1987) , Teng et al. (1988) and Quintana et al. (1991) . The different analyses show some discrepancies in the positioning of the drug along the minor groove which might be due to different crystallization conditions or dif-ferent interpretations of the electron density maps. The complex of Hoechst 33258 with the alternating sequence d(CGCGATATCGCG) has been studied by Carrondo et al. (1989) . Recently Sriram et al. (1992) have reported the complex with the dodecamer d(CGC[e'G]AATTCGCG), where e6G stands for 06-ethylguanine. In all these complexes the DNA sequence has four A . T base pairs which is approximately the length of the Hoechst dye. However the drug molecule does not bind in the same position when the central sequence is AATT or ATAT. A sequence-dependent specificity seems to drive the drug binding.
In this paper we report the structural analysis of the complex of Hoechst 33258 with the DNA dodecamer d(CGCAA-ATTTGCG). In this dodecamer the central A . T region is longer than the length of the drug and therefore several binding areas are possible along the A-tract. In the complex structure of the same dodecamer with the drugs distamycin and netropsin we have observed a single binding site (or at least a major site) rather than a disorder between several positions along the groove (Coll et al., 1987; Tabernero et al., 1993) .
We wanted to test, with a different drug, if this is a general characteristic of minor-groove-binders. In addition, the complex reported here is compared with other Hoechst 33258-DNA complexes and the influence of drug binding on the central A-tract is analyzed.
EXPERIMENTAL PROCEDURES
The DNA dodecamer d(CGCAAATTTGCG) was synthesized and purified as described (van der Marel et al., 1981) . Suitable crystals of the complex were grown by vapour diffusion at room temperature from sittings drops containing 1 mM DNA dodecamer, re-purified from previous crystallization drops by HPLC, 1 mM Hoechst-33258, 19.5% 2-methyl-2,4-pentanediol, 1 mM sodium cacodylate pH = 7 and 0.7 mM spermine, equilibrating against a reservoir of 50% 2-methyl-2,4-pentanediol.
A crystal of approximate dimensions 0.2X0.35 XO.5 mm was mounted in a glass capillary with a droplet of mother liquor. The crystal was orthorhombic, space group P2,2,2,, with unit cell dimensions a = 2.55 nm, b = 4.15 nm and c = 6.53 nm, thus being isomorphous with the original d(CGCGAATTCGCG) dodecamer (Wing et al., 1980) . Three-dimensional diffraction data were collected up to 0.24-nm resolution, at room temperature, using a Mar Research imaging plate area detector installed on an Elliot GX21 rotating anode X-ray generator.
Images were taken in 5" rotation steps with the detector set at 110mm distance. The data were processed with the MOSFLM package (Leslie, 1991) . A total of 9285 reflections were measured of which 2291 were considered unique above the 20(F0) level, and the Rmcrge was 6.1%. Table 1 shows the completeness of the data set.
The DNA coordinates from the crystal structure distamycin-d(CGCAAATTTGCG) (Coll et al., 1987) were used as a starting model. This model was first refined as a rigid body using the XPLOR package (Briinger, 1992 ) and a resolution range of 1.0-0.4 nm whereby the R-factor dropped from 33.3% to 31.2%. A combined X-ray and energy minimization refinement followed with XPLOR, increasing the resolution progressively up to 0.24 nm R here the R-factor was 31.0%. Fourier maps with coefficients 2F0-F, and Fo-F, were calculated at this point. These maps clearly showed a strong residual electron density in the DNA minor groove corresponding to the drug molecule. The Hoechst molecule was fitted into the electron density using the computer graphics program TOM-FRODO (Cambillau and Horjales, 1987 ; Jones, 1978) . Hoechst 33258 is a non-symmetrical molecule and consequently the existence of two possible orientations in the crystal was considered. Only in one orientation could the drug be fitted completely in the electron density with the bulkier piperazine ring positioned at one end of the A-tract. The structure was further refined and solvent molecules were added. The location of the drug molecule was confirmed by calculating an omit map after a refinement run excluding the drug atoms (Fig. 2) . The final R-factor is 20% for 2253 reflections between 1.0-0.24 nm. In the final structure the root-mean-square deviation from target values is 0.0019 nm for bond lengths and 3.71" for bond angles. The atomic coordinates have been deposited with the Brookhaven Protein Data Bank.
Empirical force-field calculations were performed for determining H-bond interactions using a dielectric constant E = lr. All parameters were taken from the Amber data base (Weiner et al., 1986) . Angles between mean planes of the drug were calculated with the program QUEST written by G. Quigley. DNA parameters were calculated with the program NEWHEL92 written by R. Dickerson. A16. It is therefore displaced to one end of the A-tract with the piperazine ring positioned between the T9 . A16 base pair and G10 . C15 base pair. In this area, the minor groove is less narrow than in the midst of the A-tract and the nonplanar piperazine moiety seems to fit more easily in the groove. Footprinting experiments, showing that Hoechst 33258 binds either to all-A . T segments or to A . T stretches with a G . C base pair at one edge, are in agreement with our results (Harshman and Dervan, 1985; Portugal and Waring, 1988) .
RESULTS AND DISCUSSION
Drug-DNA interactions
The N1 and N3 atoms of the benzimidazole groups of the drug (Fig. 1) interact with the bases at the floor of the minor groove by two three-centered hydrogen bonds (Fig. 4 and Table 2 ). Nitrogen N1 of the drug molecule interacts with oxygen 0 2 of thymine T7 and oxygen 0 2 of thymine T19, at the central ApT step. Nitrogen N3 is hydrogen bonded to The drug molecule is displaced from the center of the DNA sequence. Drawing generated with TURBO (Roussel & Cambillau, 1991) . the N3 atom of adenine A38 and the 0 2 atom of thymine T8. The 01 hydroxyl atom of the phenyl group at one end of the drug interacts weakly (0.36 nm) with the 04' atom from the deoxyribose of thymine T21. In the present crystal structure, as occurs in the other isomorphous dodecamer structures, the DNA molecules pack along the c axis with a two-base-pair overlap. The sugar-phosphate backbones of symmetry-related molecules are inserted at both ends of the minor groove. The terminal 03' hydroxyl atom of one of these neighbouring molecules interacts with the N6 atom of the piperazine group of the drug. Besides the hydrogen bonding interactions, the drug-DNA complex is also stabilized by van der Waals interactions between the sugar-phosphate backbone at the side walls of the groove and the TC electron density clouds of the aromatic rings (i.e. phenol group, benzimidazole groups), as occurs in other minor-groove-binding drug complexes. As mentioned above, the drug molecule is clearly displaced from the center of the A-tract leaving the A4 . T21 pair uncovered. This is in contrast with the complex structures reported with the DNA dodecamer d(CGCGAATTCGCG) (Teng et al., 1988; Quintana et al., 1991) , where the Hoechst dye occupies a more central position ( Fig. 4B and C) . The differences are obviously related to the longer A-tract present in our structure. However, because the A-tract is longer than the length of the drug, a disorder in its position along the tract could be expected. This is not the case or, at least, there is a major position and orientation of the drug molecule in the groove. The same was observed in the complex of the present sixbase-pair A-tract dodecamer with the drugs distamycin (Coll et al., 1987) and netropsin (Tabernero et al., 1993) . We note that, even though the DNA sequence is palindromic, a true crystallographic twofold axis is not present in this crystal form. The two sides of the dodecamer are different in their detailed conformations and have different packing environments. As in the distamycin and netropsin complexes, the major position and orientation of the drug must be the one with lower energy, where more drug-DNA interactions are satisfied and less repulsive contacts occur. As depicted in Fig. 4A and Table 2 , all hydrogen bond donors of the drug interact with DNA atoms, including two three-centered hydrogen bonds from N1 and N3. This kind of bifurcated hydrogen bonds imply that more H-bond acceptors in the DNA are satisfied than with single hydrogen bonds.
In the complex of Hoechst 33258 with the alternating sequence d(CGCGATATCGCG) (Carrondo et a] ., 1989) the drug molecule presents an opposite orientation with respect to the one reported here. The piperazine group is located in that structure covering the G4 . C21 base pair. The sugar moiety seems to fit better in that position where the minor groove is also less narrow. In the d(CGCAAATTTGCG) complex (this work) the piperazine does not cover a G . C (Teng et al., 1988) ; (C) Hoechst 33258-d(CGCGAATTCGCG) complex (Quintana et al., 1991) ; (D) netropsin-d(CGCAAATTTGCG) complex (Tabernero et al., 1993) ; (E) dystamicin-D(CGCAAATTTGCG) complex (Coll et al., 1987) ; (F) berenyl-d(CGCAAATTTGCG) complex . base pair but it is located where the minor groove starts to open up, four base pairs from one end of the dodecamer. A polar projection of the complex is shown in Fig. 5 . The minor groove width (represented as 04'-04' distances across the groove less their van der Waals radii) is about 0.45 nm in most of the A-tract segment (i.e. when the A and T residues face in opposite strands). The groove opens up over 0.5 nm at the G10/A18 and Cll/A17 level, the precise location of the piperazine ring. Note that although the A . T sequence is longer in the present structure, the dimensions of the minor groove are quite similar in all isomorphous dodecamer structures containing A and T residues, either continuous or alternating. An analysis of all complexes of the d(CGCAAAT-TTGCG) dodecamer with minor-groove-binders seems to indicate a widening of the groove upon drug-binding, when compared with the drug-free structure. This is not the case when the comparison is made with a redetermined native d(CGCAAATTTGCG) structure (Edwards et al., 1992) . The latter was crystallized in the presence of the minor-groovebinder pentamide, although the drug was not found to be in the crystal.
Hoechst 33258 is a molecule with three rigid planar groups. Because it is forced to follow the minor groove of the DNA double helix, there must be some torsion between the planar groups (phenol, benzimidazole 1 and 2) and between benzimidazole 2 and the piperazine ring (Fig. 1) . In all Hoechst 33258-DNA complexes the different structural groups of the drug are in different planes. The particular values of the angles between these planes are not coincident although they fall inside a range 5-37". The differences reflect the different positions of the drug which adapts to the irregular curve of the minor groove. 
DNA conformation
A-tract sequences have been found to have a high propeller twist, a base-pair conformation which might be associated with three-centered hydrogen bonds in the major groove, between the N6 atom from an adenine of one strand and two 0 4 atoms of two consecutive thymines of the opposite strand (Coll et al., 1987; Nelson et al., 1987) . In the present structure the propeller twist is clearly higher in the A . T region than in the C . G region, with an average value of -18". The average value for all G . C base pairs is -11" and only -7" when excluding base pairs G2 . C23 and C11 . G14, two base pairs that are strongly influenced by the crystal packing. The highest value of the A-tract corresponds to base pair A6 . T19 (-22") . This base pair always has a high propeller twist in all dodecamer structures, whereas a higher variability is observed in other steps. The twisting of base pair A6 . T19 allows the 0 4 atom of thymine T19 to interact with the N6 atom of the adenine A5 (Fig. 4A) . The distance between these two atoms is 0.33 nm while the distance from N6 of A5 to 0 4 of T20 (its Watson-Crick partner) is 0.30 nm. The geometry is correct for an unsymmetrical three-centered hydrogen bond between atoms of the three bases (Jeffrey et al., 1985) but the distances indicate that the cross interaction between A5 and T19 is rather weak. This interaction appears to be stronger in the distamycin complex (Coll et al., 1987) but is also weak in the native structure (Coll et al., 1987; Edwards et al., 1992) . For example we have estimated the binding energy for the cross H-bond to be -5.02 kJ/mol in the distamycin complex but only -1.68 kJ/mol in the Hoechst 33258 complex. Comparing the different d(CGCA-AATTTGCG) structures, it is apparent that a continuum on the relative position of the three atoms involved occurs, from the almost symmetric three-centered H-bond in the distamycin complex to the complete asymmetric disposition in the native dodecamer. As the asymmetry of the bifurcated bond increases (distamycin < netropsin < hoechst < native) the interaction becomes weaker.
Netropsin and distamycin seem to interact more strongly with the DNA double helix than Hoechst 33258 or berenyl resulting in a greater number of modifications of the helix parameters. The ability of netropsin and distamycin to cause a larger deformation of the DNA might be related to their capacity to establish more hydrogen bonds than Hoechst 33258 and berenyl, as can be seen in Fig. 4 . In particular, three-centered hydrogen bonds in the DNA major groove appear to be favoured by the binding of the first two drugs at least in the present sequence. Another parameter that might be strongly influenced by minor groove drug binding is the base pair buckle. The value of this parameter is high in the complex of the same d(CGCAAATTTGCG) sequence with netropsin, at step T9 . A16. This effect is not observed in the Hoechst 33258 and distamycin complexes where the buckle values are close to the ones in the native structure (Coll et al., 1987; Edwards et al., 1992) .
In agreement with previously determined complexes, the general characteristics of the A-tract (straight helix axis, high propeller twisted base pairs, three-centered hydrogen bonds in the major groove at some steps, narrow minor groove and different sugar pucker in the A and T strands) are not altered by the minor-groove-binder. In contrast to intercalators (Quigley et al., 1980; Wang et al., 1984) and drugs that bind covalently to DNA like cisplatin (Sherman et al., 1985; Coll et al., 1990) , the mode of action of these minor-groove-binding drugs does not imply a severe deformation of the DNA double helix. They rather bind in areas of the DNA where the structure of the target is already complementary to that of the drug and therefore only small induced-fit conformational changes are r61y 3T1m (of )Tj pa Td63e6at are basically the orientation of the planes of the bases in the DNA (propeller and buckle), and the torsion angles between the planar groups in the drug. 
